Gilead Sciences (LTS:0QYQ) Beginning Cash Position : $5,705 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Beginning Cash Position?

Gilead Sciences's Beginning Cash Position for the quarter that ended in Dec. 2023 was $5,705 Mil.

Gilead Sciences's quarterly Beginning Cash Position increased from Jun. 2023 ($4,937 Mil) to Sep. 2023 ($5,704 Mil) and increased from Sep. 2023 ($5,704 Mil) to Dec. 2023 ($5,705 Mil).

Gilead Sciences's annual Beginning Cash Position declined from Dec. 2021 ($5,997 Mil) to Dec. 2022 ($5,338 Mil) but then increased from Dec. 2022 ($5,338 Mil) to Dec. 2023 ($5,412 Mil).

Gilead Sciences Beginning Cash Position Historical Data

The historical data trend for Gilead Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Beginning Cash Position Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

17,940.00

11,631.00

5,997.00

5,338.00

5,412.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															4,699.00	5,411.00	4,937.00	5,704.00	5,705.00

Gilead Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Gilead Sciences Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (LTS:0QYQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (LTS:0QYQ) Headlines

No Headlines